TIDMLMT
RNS Number : 2187T
Lombard Medical Technologies PLC
18 November 2013
Lombard Medical Technologies PLC
("Lombard Medical" or "Company")
Lombard Medical Announces Formal US Launch of Aorfix(TM) at
VEITH Symposium
The Only FDA Approved Endovascular Stent Graft for Use in
Challenging Abdominal Aortic Aneurysm Cases
London, UK and Irvine, CA, November 18, 2013 - Lombard Medical
Technologies PLC (AIM: LMT), the specialist medical device company
focused on the treatment of abdominal aortic aneurysms (AAAs),
today announces a stand-alone symposium and program of
presentations to mark the formal US launch of Aorfix(TM), the
Company's flexible stent graft, at the 40(th) Annual VEITH
Symposium, November 19-23, New York Hilton Midtown Hotel,
Manhattan, New York City.
CEO of Lombard Medical Technologies, Simon Hubbert,
commented:
"Published clinical data suggest that up to 30% of patients
present with tortuous AAA anatomy. US physicians now have access to
Aorfix, a highly effective, FDA approved treatment option for such
cases. VEITH Symposium is one of the most important annual
gatherings of vascular surgeons from around the world and the ideal
venue to formally launch Aorfix in the US."
Aorfix was approved by the US FDA in February this year and
includes a unique label indication for the treatment of patients
with neck angulations up to and including 90 degrees. Lombard
Medical will be hosting a launch stand-alone symposium, where
leading physicians will present clinical data and provide their
first-hand experience of Aorfix, on Thursday November 21, 12:00
noon to 1:00 PM.
Clinical discussions at the launch stand-alone symposium will be
led by key investigators from the Pythagoras US clinical trial of
Aorfix, including:
-- Overall 1-year results of the Aorfix Pythagoras PMA Study -
Mark F. Fillinger, M.D. Director, Vascular Surgery Training
Programs, Professor of Surgery, Geisel School of Medicine,
Dartmouth and Principal Investigator for Lombard's PMA Trial
-- Anatomical angles and effect on Aorfix PMA Study results -
Mahmoud B. Malas, M.D. Chief of Endovascular Surgery and Director
of Vascular and Endovascular Clinical Research, Johns Hopkins
Bayview Medical Center
-- Gender and its impact on Aorfix PMA Study outcomes - William
D. Jordan Jr., M.D. Professor of Vascular Surgery, University of
Alabama School of Medicine
-- Access techniques for tortuous anatomy - Jeffrey P.
Carpenter, M.D. Chairman and Chief, Department of Surgery, Cooper
University Health Care
-- Clinical insights from the Aorfix PMA Study - Kim J. Hodgson,
M.D. Professor and Chair, Division of Vascular Surgery, SIU School
of Medicine
In addition, Lombard Medical will host a meeting and product
demonstration for investors and analysts on November 20, 2:30 PM to
4:30 PM at the Hilton hotel, no new material financial or other
information will be disclosed.
The following presentations highlighting Aorfix will also take
place at this year's VEITH Symposium on Friday November 22:
-- Advantages and Limitations of the Lombard Aorfix Endograft.
Now FDA Approved in the US - Mark F. Fillinger, M.D. Director,
Vascular Surgery Training Programs, Professor of Surgery, Geisel
School of Medicine, Dartmouth and Principal Investigator for
Lombard's PMA Trial
-- Challenging Anatomy: Can Freedom from Adjunctive Fixation
mean Freedom from Migration and Endoleak? - Prof. Brian R.
Hopkinson, M.D., Emeritus Professor of Vascular Surgery, University
of Nottingham; Consultant Vascular Surgeon, Queen's Medical Centre,
Nottingham, United Kingdom
-Ends-
For further information:
Lombard Medical Technologies PLC Tel: +44(0)1235 750 800
Simon Hubbert, Chief Executive Officer
Ian Ardill, Chief Financial Officer
Canaccord Genuity Limited Tel: +44(0)20 7523 8000
Lucy Tilley / Tim Redfern / Henry
Fitzgerald O'Connor / Dr Julian Feneley
FTI Consulting Tel: +44(0)20 7831 3113
Simon Conway / Stephanie Cuthbert
/ Victoria Foster Mitchell
Allen & Caron Tel: +1 (949) 474 4300
Matt Clawson
About VEITH Symposium
Now in its fourth decade, VEITH Symposium provides vascular
surgeons, interventional radiologists, interventional cardiologists
and other vascular specialists with a unique and exciting format to
learn the most current information about what is new and important
in the treatment of vascular disease. The 5-day event features 430
rapid-fire presentations from world-renowned vascular specialists
with emphasis on the latest advances, changing concepts in
diagnosis and management, pressing controversies and new
techniques. To register to attend VEITH Symposium, please visit
www.VEITHpress.org.
About Abdominal Aortic Aneurysms
AAAs are a balloon-like enlargement of the aorta which, if left
untreated, may rupture and cause death. Approximately 4.5 million
people are living with AAAs in the developed world and each year
600,000 new cases are diagnosed.
In the U.S. aortic aneurysm disease is among the leading cause
of death and it is estimated that 1.7 million people over the age
of 55 have abdominal aortic aneurysms. According to independent
market research, the U.S. AAA market is estimated at more than $600
million annually and is forecast to grow to $1.6 billion worldwide
by 2015.
About Lombard Medical
Lombard Medical Technologies PLC (AIM: LMT) is a medical device
company focused on device solutions for the $1.3 billion per annum
abdominal aortic aneurysm (AAA) repair market. The Company's lead
product, Aorfix, is an endovascular stent graft which has been
specifically designed to solve the problems that exist in treating
complex tortuous anatomy, which is often present in advanced AAA
disease. Aorfix is the only stent graft approved for AAA neck
angulations of up to 90 degrees and is currently being
commercialized worldwide. Aorfix is the first AAA stent graft not
of U.S. origin to gain FDA approval. The Company is headquartered
in Oxfordshire, England with U.S. operations in Irvine, CA.
Further background on the Company can be found at
www.lombardmedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
PRLDELFFXFFXFBK
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Nov 2023 to Nov 2024
